Application of Nuclear Imaging Probes in PD-L1 Immunotherapy of Tumor

Immunotherapy strategies of targeting PD-1 and its ligand PD-L1 are widely administered in varied types of cancer. Patient benefitting from PD-L1 targeted immunotherapy mainly depends on the expression level of PD-L1 in tumor tissues. Currently, the expression level of PD-L1 is primarily detected th...

Full description

Saved in:
Bibliographic Details
Published inZhongliu fangzhi yanjiu Vol. 48; no. 12; pp. 1123 - 1128
Main Authors Yang, Linchao, Li, Wenjie, Chen, Nan
Format Journal Article
LanguageChinese
Published Tianjin China Anti-Cancer Association 01.12.2021
Magazine House of Cancer Research on Prevention and Treatment
Subjects
Biopsy
Heterogeneity
Immunotherapy
Invasiveness
Medical imaging
molecular imaging
Nuclear medicine
Patients
PD-1 protein
pd-l1
PD-L1 protein
Probes
small-molecule inhibitors
Spatial heterogeneity
tumor
Tumors
Online AccessGet full text

Cover

More Information
Summary:Immunotherapy strategies of targeting PD-1 and its ligand PD-L1 are widely administered in varied types of cancer. Patient benefitting from PD-L1 targeted immunotherapy mainly depends on the expression level of PD-L1 in tumor tissues. Currently, the expression level of PD-L1 is primarily detected through the invasive method of biopsy in clinic, which is severely limited by the temporal and spatial heterogeneity of PD-L1 expression. Nuclear medicine probe can realize the noninvasive as well as in vivo detection of PD-L1 at the molecular level, which has important clinical significance for the guidance of patient screening and the prediction of patient's response to immunotherapy. This article reviews PD-L1 targeting nuclear imaging probes and their applications in tumor PD-L1 imaging.
ISSN:1000-8578
DOI:10.3971/j.issn.1000-8578.2021.21.0673